292 related articles for article (PubMed ID: 35945201)
1. Raptor downregulation rescues neuronal phenotypes in mouse models of Tuberous Sclerosis Complex.
Karalis V; Caval-Holme F; Bateup HS
Nat Commun; 2022 Aug; 13(1):4665. PubMed ID: 35945201
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
3. Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex.
Carson RP; Fu C; Winzenburger P; Ess KC
Hum Mol Genet; 2013 Jan; 22(1):140-52. PubMed ID: 23049074
[TBL] [Abstract][Full Text] [Related]
4. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.
Feliciano DM; Lin TV; Hartman NW; Bartley CM; Kubera C; Hsieh L; Lafourcade C; O'Keefe RA; Bordey A
Int J Dev Neurosci; 2013 Nov; 31(7):667-78. PubMed ID: 23485365
[TBL] [Abstract][Full Text] [Related]
5. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
6. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
[TBL] [Abstract][Full Text] [Related]
7. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
8. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
Misra UK; Pizzo SV
PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
[TBL] [Abstract][Full Text] [Related]
9. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.
Way SW; Rozas NS; Wu HC; McKenna J; Reith RM; Hashmi SS; Dash PK; Gambello MJ
Hum Mol Genet; 2012 Jul; 21(14):3226-36. PubMed ID: 22532572
[TBL] [Abstract][Full Text] [Related]
10. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
11. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency.
Chen CJ; Sgritta M; Mays J; Zhou H; Lucero R; Park J; Wang IC; Park JH; Kaipparettu BA; Stoica L; Jafar-Nejad P; Rigo F; Chin J; Noebels JL; Costa-Mattioli M
Nat Med; 2019 Nov; 25(11):1684-1690. PubMed ID: 31636454
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
14. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex.
Nie D; Chen Z; Ebrahimi-Fakhari D; Di Nardo A; Julich K; Robson VK; Cheng YC; Woolf CJ; Heiman M; Sahin M
J Neurosci; 2015 Jul; 35(30):10762-72. PubMed ID: 26224859
[TBL] [Abstract][Full Text] [Related]
15. Complex Neurological Phenotype in Mutant Mice Lacking Tsc2 in Excitatory Neurons of the Developing Forebrain(123).
Crowell B; Lee GH; Nikolaeva I; Dal Pozzo V; D'Arcangelo G
eNeuro; 2015; 2(6):. PubMed ID: 26693177
[TBL] [Abstract][Full Text] [Related]
16. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
17. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressors TSC1 and TSC2 differentially modulate actin cytoskeleton and motility of mouse embryonic fibroblasts.
Goncharova EA; James ML; Kudryashova TV; Goncharov DA; Krymskaya VP
PLoS One; 2014; 9(10):e111476. PubMed ID: 25360538
[TBL] [Abstract][Full Text] [Related]
19. mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex.
Pema M; Drusian L; Chiaravalli M; Castelli M; Yao Q; Ricciardi S; Somlo S; Qian F; Biffo S; Boletta A
Nat Commun; 2016 Mar; 7():10786. PubMed ID: 26931735
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic Screen with TSC-Deficient Neurons Reveals Heat-Shock Machinery as a Druggable Pathway for mTORC1 and Reduced Cilia.
Di Nardo A; Lenoël I; Winden KD; Rühmkorf A; Modi ME; Barrett L; Ercan-Herbst E; Venugopal P; Behne R; Lopes CAM; Kleiman RJ; Bettencourt-Dias M; Sahin M
Cell Rep; 2020 Jun; 31(12):107780. PubMed ID: 32579942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]